- Home
- EVOK vs ATNF Comparison
EVOK vs ATNF Comparison
Compare EVOK & ATNF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVOK
- ATNF
- Stock Information
- Founded
- EVOK 2007
- ATNF 2016
- Country
- EVOK United States
- ATNF United States
- Employees
- EVOK N/A
- ATNF N/A
- Industry
- EVOK Biotechnology: Pharmaceutical Preparations
- ATNF Biotechnology: Pharmaceutical Preparations
- Sector
- EVOK Health Care
- ATNF Health Care
- Exchange
- EVOK Nasdaq
- ATNF Nasdaq
- Market Cap
- EVOK 4.2M
- ATNF 5.0M
- IPO Year
- EVOK 2013
- ATNF N/A
- Fundamental
- Price
- EVOK $2.70
- ATNF $0.88
- Analyst Decision
- EVOK
- ATNF
- Analyst Count
- EVOK 0
- ATNF 0
- Target Price
- EVOK N/A
- ATNF N/A
- AVG Volume (30 Days)
- EVOK 19.3K
- ATNF 40.3K
- Earning Date
- EVOK 08-12-2025
- ATNF 08-11-2025
- Dividend Yield
- EVOK N/A
- ATNF N/A
- EPS Growth
- EVOK N/A
- ATNF N/A
- EPS
- EVOK N/A
- ATNF N/A
- Revenue
- EVOK $11,594,083.00
- ATNF N/A
- Revenue This Year
- EVOK $57.82
- ATNF N/A
- Revenue Next Year
- EVOK $59.12
- ATNF N/A
- P/E Ratio
- EVOK N/A
- ATNF N/A
- Revenue Growth
- EVOK 89.89
- ATNF N/A
- 52 Week Low
- EVOK $1.94
- ATNF $0.66
- 52 Week High
- EVOK $12.32
- ATNF $17.75
- Technical
- Relative Strength Index (RSI)
- EVOK 43.42
- ATNF 42.06
- Support Level
- EVOK $2.50
- ATNF $0.95
- Resistance Level
- EVOK $2.84
- ATNF $0.96
- Average True Range (ATR)
- EVOK 0.20
- ATNF 0.07
- MACD
- EVOK -0.01
- ATNF 0.00
- Stochastic Oscillator
- EVOK 47.45
- ATNF 27.73
About EVOK Evoke Pharma Inc.
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.
About ATNF 180 Life Sciences Corp.
180 Life Sciences Corp was formed as a clinical-stage biotechnology company, focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation, and fibrosis by employing research, and, where appropriate, combination therapy. In addition, it has acquired certain source code and intellectual property relating to the back-end technology platform to operate an online blockchain casino, and moving forward, it plans to focus the majority of its operations on the creation of the online blockchain casino, while looking to monetize certain prior development-stage therapeutic product candidates for unmet medical needs. It has one reportable operating segment, iGaming.